Alzheimer’s drug development pipeline: Promising therapies, pharma investment drive momentum in clinical trials

Pipeline highlights

• 187 current trials, which consist of 141 unique treatments—just off last year’s record of 143 unique treatments
• 58 new drugs have entered the pipeline in the past year
• DMTs are the most common agents used in trials: 111 agents, or 79%, of the total number of drugs in the pipeline
• 28% of candidate therapies are repurposed from other diseases
• 57,465 participants are needed for all currently active trials

Biologics gaining momentum

Pharma investment growing

Recruitment struggles slowing progress

Source: Read Full Article